Delcath Systems, Inc. (NASDAQ:DCTH) Shares Purchased by Bank of America Corp DE

Bank of America Corp DE lifted its stake in Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 1,816.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 25,700 shares of the company's stock after purchasing an additional 24,359 shares during the quarter. Bank of America Corp DE owned about 0.08% of Delcath Systems worth $309,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Quarry LP acquired a new position in Delcath Systems during the 4th quarter valued at approximately $34,000. Quantbot Technologies LP purchased a new stake in shares of Delcath Systems during the fourth quarter valued at $66,000. Private Advisor Group LLC acquired a new position in shares of Delcath Systems in the 4th quarter valued at $153,000. Charles Schwab Investment Management Inc. acquired a new position in shares of Delcath Systems in the 4th quarter valued at $156,000. Finally, Tower Research Capital LLC TRC raised its stake in Delcath Systems by 1,161.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 14,694 shares of the company's stock worth $177,000 after acquiring an additional 13,529 shares during the last quarter. 61.12% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

DCTH has been the topic of several research analyst reports. Wall Street Zen downgraded Delcath Systems from a "strong-buy" rating to a "buy" rating in a research note on Sunday, June 1st. HC Wainwright reaffirmed a "buy" rating and set a $29.00 target price (up previously from $24.00) on shares of Delcath Systems in a report on Friday, May 23rd. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $24.00.

Delcath Systems Stock Performance

NASDAQ DCTH traded down $0.80 on Tuesday, reaching $14.63. 493,187 shares of the company's stock traded hands, compared to its average volume of 390,042. Delcath Systems, Inc. has a fifty-two week low of $7.17 and a fifty-two week high of $18.23. The firm has a market cap of $509.56 million, a price-to-earnings ratio of -29.26 and a beta of 0.95. The stock has a 50 day moving average price of $14.24 and a 200-day moving average price of $13.67.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.07). Delcath Systems had a negative net margin of 26.38% and a negative return on equity of 29.44%. The company had revenue of $19.80 million during the quarter, compared to analyst estimates of $16.83 million. As a group, equities research analysts anticipate that Delcath Systems, Inc. will post -0.79 EPS for the current fiscal year.

Delcath Systems Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.